You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 14, 2025

LIBTAYO Drug Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Tradename: LIBTAYO
High Confidence Patents:0
Applicants:1
BLAs:1
Recent Clinical Trials: See clinical trials for LIBTAYO
Recent Clinical Trials for LIBTAYO

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Genzyme, a Sanofi CompanyPhase 2
OncoNano Medicine, Inc.Phase 1
Regeneron PharmaceuticalsPhase 2/Phase 3

See all LIBTAYO clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for LIBTAYO Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for LIBTAYO Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for LIBTAYO Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for the Biologic Drug: Libtayo

Introduction

Libtayo, a monoclonal antibody targeting the immune checkpoint receptor PD-1 on T-cells, has been a significant player in the oncology market since its approval in 2018. Developed by Sanofi and Regeneron, this drug has undergone substantial changes in its commercialization and financial performance over the years.

Development and Approval History

Libtayo was approved by the FDA in 2018 for advanced cutaneous squamous cell carcinoma. Subsequently, it received additional indications for advanced basal cell carcinoma and first-line advanced non-small cell lung cancer with PD-L1 expression of at least 50% in 2021[1][4].

Commercialization and Partnership

Initially, Sanofi and Regeneron shared the commercialization responsibilities for Libtayo, with Sanofi handling the rest of the world and both companies splitting profits equally in the U.S. However, in June 2022, Regeneron acquired the exclusive international rights to Libtayo from Sanofi for $900 million. This deal also included potential additional payments of up to $200 million based on regulatory approvals and sales milestones, along with an 11% royalty on global sales[1][4].

Financial Performance

Pre-Acquisition

Before Regeneron's acquisition, Libtayo generated $306 million in sales for Regeneron and €129 million for Sanofi in 2021. These figures were part of the broader oncology portfolio for both companies[1].

Post-Acquisition

Following the acquisition, Regeneron reported a significant increase in Libtayo sales. In the fourth quarter of 2023, global net sales of Libtayo increased by 44% to $244 million compared to the same period in 2022. For the full year 2023, global net sales of Libtayo rose by 50% to $869 million[2].

Market Position and Competition

Libtayo entered a crowded market dominated by other PD-1 inhibitors such as Merck's Keytruda, Bristol Myers Squibb's Opdivo, and Roche's Tecentriq. Despite being the sixth PD-1 inhibitor to market, Libtayo has carved out a niche, particularly in non-melanoma skin cancer where it is considered a standard of care[4].

Competitive Landscape

The competitive landscape in cancer immunotherapy is intense, with leading drugs like Keytruda generating significantly higher revenues. For example, Keytruda earned $17 billion in 2021, while Libtayo's sales were $444 million in the same year. However, Regeneron is optimistic about Libtayo's potential, especially with its combination therapies and strong data in chemotherapy combinations[4].

Regulatory Milestones and Future Prospects

Regeneron is awaiting key regulatory decisions, including the FDA's review of Libtayo's use with chemotherapy in newly diagnosed patients with non-small cell lung cancer. This approval could significantly boost Libtayo's market position[1][4].

Combination Therapies

Regeneron is also exploring combination therapies involving Libtayo and other immunotherapies, such as LAG-3 inhibitors and bispecific antibodies. These combinations are expected to generate results in the coming years and could provide a competitive edge in the market[4].

Financial Impact on Regeneron

The acquisition of Libtayo is expected to have a neutral impact on Regeneron's revenues in the short term but is anticipated to add to sales and profits over the long term. The deal also accelerates the repayment of $3.5 billion in development costs, reducing the repayment period by three to five years[4].

Revenue Growth

Regeneron's overall financial performance has been strong, with revenue growth of 14% and 12% in the fourth quarter and full year 2023, respectively, excluding contributions from Ronapreve. The acquisition of Libtayo has contributed to this growth, reflecting the company's continued strength across its business[2].

Analyst Insights

Analysts have noted that the deal enhances Regeneron's developmental flexibility and is relatively low-cost compared to the company's cash holdings. However, the full value of the transaction may not be clear for several years, especially given the competitive landscape and the potential for biosimilars in the long term[4].

Conclusion

Libtayo's market dynamics and financial trajectory are marked by significant milestones, including its acquisition by Regeneron and its growing sales performance. As the oncology landscape continues to evolve, Libtayo's position as a key player in cancer immunotherapy is solidifying, driven by its approvals, combination therapies, and strong commercial execution.

Key Takeaways

  • Acquisition and Rights: Regeneron acquired exclusive international rights to Libtayo from Sanofi for $900 million.
  • Sales Growth: Libtayo's global net sales increased by 50% to $869 million in 2023.
  • Market Position: Libtayo competes in a crowded PD-1 inhibitor market but has a strong niche in non-melanoma skin cancer.
  • Regulatory Milestones: Awaiting FDA decisions on new indications, including use with chemotherapy in non-small cell lung cancer.
  • Combination Therapies: Exploring combinations with other immunotherapies to enhance competitiveness.
  • Financial Impact: Expected to add to Regeneron's sales and profits over the long term.

FAQs

Q: What is Libtayo and how does it work?

Libtayo is a monoclonal antibody that targets the immune checkpoint receptor PD-1 on T-cells, helping the immune system recognize and attack cancer cells.

Q: Who developed and commercialized Libtayo initially?

Libtayo was developed by Sanofi and Regeneron, with both companies initially sharing commercialization responsibilities.

Q: What was the financial arrangement when Regeneron acquired the rights to Libtayo?

Regeneron paid $900 million to Sanofi, with potential additional payments of up to $200 million based on regulatory approvals and sales milestones, along with an 11% royalty on global sales.

Q: How has Libtayo's sales performance been since the acquisition?

Libtayo's global net sales increased by 50% to $869 million in 2023, reflecting strong commercial execution by Regeneron.

Q: What are the key future prospects for Libtayo?

Regeneron is awaiting key regulatory decisions and is exploring combination therapies to enhance Libtayo's competitiveness in the market.

Sources

  1. Drug Discovery Trends: Regeneron purchases exclusive rights to Libtayo from Sanofi for $900m.
  2. Regeneron Investor Relations: Regeneron Reports Fourth Quarter and Full Year 2023 Financial.
  3. Sanofi Press Release: Sanofi Q2: strong performance with 10% sales growth; 2024.
  4. BioPharma Dive: Regeneron buys control of cancer drug Libtayo from Sanofi.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.